A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period

Diabetes Research and Clinical Practice

Volumn 79, Issue 2, 2008, Pages 269-275

  Luzio, Stephen ^a   Peter, Rajesh ^a   Dunseath, Gareth J ^a   Mustafa, Laila ^a   Owens, David R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Glulisine; Lispro; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN GLULISINE; INSULIN LISPRO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TEST MEAL;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY;

EID: 38349087531     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.11.013     Document Type: Article

References (27)

1. Luzio S.D., Peter R., Dunseath G.J., Mustafa N., and Owens D.R. Comparison of the pharmacodynamics and pharmacokinetics of bolus subcutaneous insulin glulisine and insulin lispro in obese patients with type 2 diabetes. Diabetologia 48 (2005) A307 (Abstract 844)
2. Luzio S.D., Peter R., Dunseath G.J., Mustafa N., and Owens D.R. The pharmacokinetics and pharmacodynamics of insulin glulisine compared with insulin lispro in obese patients with type 2 diabetes. Diabet. Med. 23 (2006) 42 (Abstract P47)
3. Bethel M.A., and Feinglos M.N. Basal insulin therapy in type 2 diabetes. J. Am. Board Fam. Pract. 18 (2005) 199-204
4. Binder C., Lauritzen T., Faber O., and Pramming S. Insulin pharmacokinetics. Diabetes Care 7 (1984) 188-199
5. American Diabetes Association, Insulin Administration, Diabetes Care 26 (2003) S121-S124.
6. Owens D.R., Zinman B., and Bolli G.B. Insulins today and beyond. Lancet 358 (2001) 739-746
7. Garg S.K., Rosenstock J., and Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr. Pract. 11 (2005) 11-17
8. Garg S.K., Ellis S.L., and Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin. Pharmacother. 6 (2005) 643-651
9. Dreyer M., Prager R., Robinson A., Busch K., Ellis G., and Souhami E. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm. Metab. Res. 37 (2005) 702-707
10. Becker R.H.A., Frick A.D., Kapitza C., Heise T., and Rave K. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes. Diabetes 53 (2004) A119 (Abstract 503-P)
11. Dailey G., Rosenstock J., Moses R.G., and Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27 (2004) 2363-2368
12. Hauner H. Managing type 2 diabetes mellitus in patients with obesity. Treat. Endocrinol. 3 (2004) 223-232
13. Barnett A.H. How well do rapid-acting insulins work in obese individuals?. Diabetes Obes. Metab. 8 (2006) 388-395
14. Vora J.P., Burch A., Peters J.R., and Owens D.R. Absorption of radiolabelled soluble insulin in type 1 (insulin-dependent) diabetes: influence of subcutaneous blood flow and anthropometry. Diabet. Med. 10 (1993) 736-743
15. Becker R.H., Frick A.D., Burger F., Potgieter J.H., and Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp. Clin. Endocrinol. Diabetes 113 (2005) 435-443
16. UKPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352 (1998) 837-853.
17. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (1995) 103-117
18. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
19. Hirsch I.B., and Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J. Diabetes Complications 19 (2005) 178-181
20. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
21. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
22. Monnier L., Colette C., Dunseath G.J., and Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
23. Rosskamp R.H., and Park G. Long-acting insulin analogs. Diabetes Care 22 (1999) B109-B113
24. Becker R.H. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol. Ther. 9 (2007) 109-121
25. Sluzky V., Tamada J.A., Klibanov A.M., and Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 9377-9381
26. Bakaysa D.L., Radziuk J., Havel H.A., Brader M.L., Li S., Dodd S.W., et al. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Sci. 5 (1996) 2521-2531
27. Bhatnagar S., Srivastava D., Jayadev M.S., and Dubey A.K. Molecular variants and derivatives of insulin for improved glycemic control in diabetes. Prog. Biophys. Mol. Biol. 91 (2006) 199-228